Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKK 08/23: Darolutamide added to first-line treatment of metastatic castration-resistant prostate cancer
2024-512132-29-00Phase 2Authorised
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Standard-of-care first-line mCRPC therapy with Standard-of-care plus darolutamide (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start May 2025; status: authorised.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-512132-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512132-29-00.